Funding Opportunity PAR-21-160 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to seek UG3/UH3 phased cooperative agreement research applications to plan and implement clinical trials within the mission of NIDCR. Awards made under this FOA will initially support a one-year milestone-driven planning phase (UG3), with possible transition to a clinical trial implementation phase of up to five years (UH3). Only UG3 projects that have met the scientific milestones and feasibility requirements may transition to the UH3 phase. The UG3/UH3 application must be submitted as a single application, following the instructions described in this FOA. The UH3 phase of the award will support the conduct of one investigator-initiated clinical trial.

£40000 - £50000 per annum: Hyper Recruitment Solutions (HRS): We are currently looking for a Bioinformatics Pipeline Developer to join a leading Biotech company based in the Cambridgeshire area. As the Bioinformatics Pipeline Developer... Cambridgeshire

Competitive Salary: EMBL: About this position The European Bioinformatics Institute (EMBL-EBI) is seeking to recruit a highly motivated Lead Data Scientist/Bioinformatician Hinxton, Cambridgeshire, England

Competitive Salary: EMBL: About this position We are seeking an experienced and motivated full-stack software developer to work on cutting-edge genome resources at the EMBL Hinxton, Cambridgeshire, England

Competitive Salary: EMBL: About this position We are seeking to recruit an experienced Accounts Assistant to work in our small Finance and Purchasing team at the European Bi Hinxton, Cambridgeshire, England

Games offer fun, low-stakes opportunities to practice communicating and learning from mistakes, this researcher writes

Notice NOT-GM-21-018 from the NIH Guide for Grants and Contracts

Notice NOT-EB-21-007 from the NIH Guide for Grants and Contracts

Notice NOT-DK-21-012 from the NIH Guide for Grants and Contracts

Notice NOT-MH-21-125 from the NIH Guide for Grants and Contracts

Notice NOT-MD-21-015 from the NIH Guide for Grants and Contracts

Competitive Salary: EMBL: About this position We are seeking to recruit energentic Project Leader to help develop and manage the Ensembl Plants resource (and related resourc Hinxton, Cambridgeshire, England

Notice NOT-MD-21-014 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-AG-22-020 from the NIH Guide for Grants and Contracts. The goal of this initiative is to support research that can lead to the development of interventions for optimizing communication among patients, caregivers, and health care practitioners, and for preserving strong and supportive caregiving relationships throughout disease progression along the continuum of care for people with AD/ADRD. To these ends, basic research and translational research is solicited in two high-priority areas: (1) effective communications and relationships among patients, healthcare practitioners, and caregivers; and (2) associations between close relationship processes and health in caregiving relationships.

Notice NOT-MH-21-105 from the NIH Guide for Grants and Contracts

Notice NOT-HS-21-010 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-21-137 from the NIH Guide for Grants and Contracts. This is a reissue of RFA-MH-18-702: Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R61/R33- Clinical Trial Required). NIMH requires an experimental therapeutics approach for the development and testing of therapeutic interventions, in which studies both evaluate the clinical effect of an intervention and generate information about the mechanisms underlying a disorder or an intervention response. As part of NIMHs Clinical Trial Pipeline, this FOA encourages early stage testing of pharmacologic interventions with novel mechanisms of actions or device-based interventions. More specifically, this FOA is intended to support early stage testing of pharmacologic or device-based interventions using a protocol design where the presumed mechanism of action of the intervention is adequately tested, to provide meaningful information where target modulation yields a dose-dependent neurophysiological/clinical/behavioral effect.

Funding Opportunity PAR-21-136 from the NIH Guide for Grants and Contracts. This is a reissue of RFA-MH-18-703: Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R33- Clinical Trial Required). NIMH requires an experimental therapeutics approach for the development and testing of therapeutic interventions, in which studies both evaluate the clinical effect of an intervention and generate information about the mechanisms underlying a disorder or an intervention response. As part of NIMHs Clinical Trial Pipeline, this FOA encourages early stage testing of pharmacologic interventions with novel mechanisms of actions or device-based interventions. More specifically, this FOA is intended to support early stage testing of pharmacologic or device-based interventions using a protocol design where the presumed mechanism of action of the intervention is adequately tested, to provide meaningful information where target modulation yields a dose-dependent neurophysiological/clinical/behavioral effect.

Funding Opportunity PAR-21-135 from the NIH Guide for Grants and Contracts. This is a reissue of RFA-MH-18-704: Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R61/R33 Clinical Trial Required). As part of NIMH's clinical trials pipeline, this FOA encourages pilot research developing and testing novel psychosocial interventions and/or targets. Consistent with NIMH's emphasis on the experimental therapeutics approach to intervention development, it intends to speed the translation of emergent research in basic, behavioral, cognitive, affect, and neuropsychological science into preventative or therapeutic interventions. This RFA will provide up to two years of support for evaluation of target engagement and establishment of intervention parameters, and up to three years of support to replicate target engagement from prior studies and to test the association between target engagement and change in clinical outcome(s).

Funding Opportunity PAR-21-129 from the NIH Guide for Grants and Contracts. This is a reissue of RFA-MH-18-700: Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (Collaborative R01-- Clinical Trial Required). This FOA is a key element of NIMHs set of FOAs to support clinical trials research across the intervention development and testing pipeline. The FOA supports (1) clinical trials to test the effectiveness of optimized therapeutic and preventive interventions for use in community and practice settings; and (2) clinical trials to evaluate the effectiveness of patient-, provider-, organizational-, or systems-level services interventions to improve access, continuity, quality, equity, and/or value of mental health services. This FOA is intended to support trials that: address a significant problem, such that the findings have potential to inform practice; are adequately powered to definitively answer the primary research question(s), with well-justified hypotheses supported by pilot data; and are designed to examine questions regarding mediators and moderators of effects. Consistent with the NIMH experimental therapeutics approach, this FOA is intended to support effectiveness trials that explicitly address whether the intervention engages the target(s)/mechanism(s) presumed to underlie the intervention effects (i.e., the mechanism(s) that accounts for changes in clinical/functional outcomes, changes in provider behavior, improved access or continuity of services, etc.). The collaborative R01 mechanism provides support for multisite trials when two or more sites are necessary for completion of the trial (e.g., to increase sample size, accelerate recruitment, or increase sample diversity and representation).